For research and educational purposes only. Not medical advice.

Triptorelin Reference

Educational, not medical advice reference for Triptorelin: Reproductive, Hormonal; regulatory status, evidence posture, source review, and sched…

Reference summary

Triptorelin is a long-acting synthetic decapeptide GnRH agonist. Like leuprolide and goserelin, sustained receptor occupancy produces pituitary downregulation and reversible medical castration after a transient initial gonadotropin surge. The Trelstar US label is anchored in advanced prostate cancer, with the 3.75 mg one-month, 11.25 mg three-month, and 22.5 mg six-month formulations established by registration trials demonstrating sustained castration-level testosterone. Outside the US, decades of European data also support GnRH-agonist use in pediatric central precocious puberty and adult endometriosis; the US Trelstar label does not include those uses.

Regulatory and posture

Categories
Reproductive, Hormonal
Aliases
Trelstar, GnRH agonist depot, Triptorelin pamoate, Decapeptyl, AY-25650
Evidence posture
human - Oncology drug. Prescription-only and clinician-administered as an intramuscular depot; off-label or self-administered use is not safe and is outside FDA approval. Tumor flare during the initial surge phase is a labeled risk in advanced prostate cancer; QT/QTc prolongation and cardiovascular risk are class-level androgen-deprivation concerns.
Regulatory status
FDA-approved prescription medication (Trelstar) for palliative treatment of advanced prostate cancer. Prescription-only and clinician-administered. Outside the US, triptorelin (Decapeptyl, Diphereline) carries additional approved indications including endometriosis, uterine fibroids, central precocious puberty, breast cancer, and male infertility from idiopathic oligozoospermia in several European markets; pepSmart only references the US Trelstar label.
Content review status
label verified

Selected public sources

Related tools